Contact Us
.svg)
2025 Q4 Healthcare Market Report
$21B in headline acquisitions, $4.3B in new venture funds, and biotech outperformance signal renewed momentum across healthcare
Echo Partners' Q4 2025 Healthcare Market Report covers key developments across venture capital fundraising, flagship venture and strategic M&A transactions, and the broader macro environment heading into 2026.
Notable Q4 highlights include over $4.3 billion in new healthcare-focused venture funds reaching final close, led by TCGX Fund III ($1.3B) and Sofinnova Capital XI ($750M). Flagship venture rounds continued at scale, with Kailera's $600M Series B and Tubulis' $361M Series C reflecting sustained institutional appetite for clinical-stage assets in obesity and oncology. On the strategic side, the quarter saw several landmark acquisitions, including Abbott's approximately $21 billion acquisition of Exact Sciences and Novartis' $12 billion acquisition of Avidity Biosciences.
Public equities closed the year higher, with the iShares Biotechnology ETF (IBB) up 27.65% on a trailing twelve-month basis, significantly outpacing the S&P 500 Healthcare Index at 12.53%, driven by improving risk appetite and renewed M&A and licensing activity across life sciences.